Skip to Content

Breast Imaging Study Publications

Primary Study Publications

Peters JA, Kenen R, Giusti R, Loud J, Weissman N, Greene MH. Exploratory study of the feasibility and utility of the colored eco-genetic relationship map (CEGRM) in women at high genetic risk of developing breast cancer. Am J Med Genet A 2004; 130A:258-64

Abati A, Greene MH, Filie A, Loud J, Prindiville S, Danforth D, Giusti RM: Quantification of the cellular components of breast duct lavage samples. Diagn Cytopathol 2006; 34:78-81

Loud JT, Weissman NE, Peters JA, Giusti RM, Wilfond BS, Burke W, Greene MH. Deliberate deceit of family members: a challenge to providers of clinical genetics services. J Clin Oncol 2006;2 4:1643-1646

Peters JA, Hoskins LM, Prindiville S, Kenen R, Greene MH: Evolution of the colored eco-genetic relationship map (CEGRM) for assessing social functioning in women in hereditary breast-ovarian (HBOC) families. J Genetic Counsel 2006; 15:477-89

Bakos AD, Hutson SP, Loud JT, Peters JA, Giusti RM, Greene MH. BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience. Health Expect 2008; 11:220-31 

Hoskins LM, Roy K, Peters JA, Loud JT, Greene MH. Disclosure of positive BRCA1/2-mutation status in young couples: The journey from uncertainty to bonding through partner support. Families Systems and Health 2008; 26:296-316

Koehly LM, Peters JA, Kuhn N, Hoskins LM, Letocha A, Kenen R, Loud J, Greene MH. Sisters in hereditary breast and ovarian cancer families: communal coping, social integration, and psychological well-being. Psycho-Oncology 2008; 17:812-21

Mueller CM, Mai PL, Bucher J, Peters JA, Loud JT, Greene MH. Complementary and alternative medicine use among women at increased genetic risk of breast and ovarian cancer. BMC Complement Altern Med 2008; 8:17, E-pub

Koehly LM, Peters JA, Kenen R, Hoskins LM, Ersig AL, Kuhn NR, Loud JT, Greene MH. Characteristics of health information gatherers, disseminators, and blockers within families at risk of hereditary cancer: implications for family health communication interventions. Am J Public Health 2009; 99:2203-2209

Loud JT, Beckjord EB, Nichols K, Peters J, Giusti R, Greene MH. Tolerability of breast ductal lavage in women from families at high genetic risk of breast cancer. BMC Womens Health 2009; 9:20, E-pub

Loud JT, Thiebaut AC, Abati AD, Filie AC, Nichols K, Danforth D, Giusti R, Prindiville SA, Greene MH. Ductal lavage in women from BRCA1/2 families: is there a future for ductal lavage in women at increased genetic risk of breast cancer? Cancer Epidemiol Biomarkers Prev 2009; 18:1243-1251

Gierach GL, Loud JT, Chow CK, Prindiville SA, Eng-Wong J, Soballe PW, Giambartolomei C, Mai PL, Galbo CE, Nichols K, Calzone KA, Vachon C, Gail MH, Greene MH. Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer. Breast Cancer Res Treat 2010; 123:245-255

Freed M, de Zwart JA, Loud JT, El Khouli RH, Myers KJ, Greene MH, Duyn JH, Badano A: An anthropomorphic phantom for quantitative evaluation of breast MRI. Med Phys 2011;38:743-753

Peters JA, Kenen R, Hoskins LM, Koehly LM, Graubard R, Loud JT, Greene MH. Unpacking the blockers: Understanding perceptions and social constraints of health communication in hereditary breast/ovarian cancer (HBOC) susceptibility families. J Genet Couns 2011; 20(5):  (2011):450-464

Hoskins LM, Roy K, Greene MH. Toward a new understanding of risk perception among young female BRCA1/2 “previvors”. Family Systems and Health 2012; 30(1): 32-46

Werner-Lin A, Hoskins LM, Doyle M, Greene MH. Cancer doesn’t have an age: Genetic testing and cancer risk management in BRCA1/2 mutation-positive women aged 18-24. Health 2012; 16(6):636-654

Hoskins LM, Greene MH. Anticipatory loss and early mastectomy for young female BRCA1/2 mutation carriers. Qualitative Health Research 2012; 22(12) 1633–1646

Jacobs KB, Yeager M, Zhou W, Kratz CP, Greene MH, et al. Detectable clonal mosaicism and its relationship to aging and cancer.  Nature Genetics 2012; 44:651-658

Consortium of Modifiers of BRCA1/2 (CIMBA) Collaboration

Spurdle AB, et al. The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2006; 15:76-79

Couch FJ, et al. AURKA F31I Polymorphism and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A CIMBA study. Cancer Epidemiol Biomarkers Prev 2007; 16:1416-1421

Chenevix-Trench G, et al. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res 2007; 9:104-107

Antoniou AC, et al. RAD51 135G>C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genetics 2007; 81:1186-1200

Osorio A, Pollan M, Pita G, et al. on behalf of CIMBA. An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2008; 99:974-977

Antoniou AC, et al. Common breast cancer predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008; 82:937-948

Rebbeck TR, et al. No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. Breast Ca Res Treat 2009; 115:185-192

Sinilnikova O, et al. The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2009; 101:1456–1460

Antoniou AC, et al. Common variants in 8q24, LSP1 and 2q35 and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Hum Molec Genet 2009; 18:4442-56

Osorio A, et al. Evaluation of a candidate breast cancer associated SNP in ERCC4 as a phenotypic modifier in BRCA1/2 mutation carriers. Br J Cancer 2009; 101: 2048-54

Engel C, et al. Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2010; 19:2859-2868

Antoniou AC, et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Research 2010; 70:9742-9754

Antoniou AC, et al. A genome-wide association study identifies a 19p13 locus that modifies the risk of breast cancer in BRCA1 mutation carriers and which is associated with estrogen receptor-negative and triple-negative breast cancer in the general population. Nature Genetics 2010; 42(10):885-92

Gaudet MM, et al. Common genetic variants and modification of penetrance of BRCA2-Associated breast cancer. PLoS Genetics 2010; 6(10), e1001183

Ramus SJ, et al. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2011; 103:105-116

Jakubowska A, et al. The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers. Br Cancer Res Treat 2010; 121:639-649

Im KM, et al. BRCA2 haplotype structure in Ashkenazi Jewish 6174delT mutation carriers. Human Genet 2011; 130:685-699

Antoniou AC, et al. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molec Genet 2011; 15: 20:3304-3321

Cox DG, et al. Common variants of the BRCA1 wild-type allele modify the risk of  breast cancer in BRCA1 mutation carriers. Human Molec Genet 2011; 20:4732-4747

Mulligan AM, et al. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers. Br Cancer Res 2011; 13: R110, E-pub

Mavaddat N, et al. Pathology of breast and ovarian Cancers among BRCA1 and BRCA2 mutation carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012; 21 134-147

Bolton KL, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA2012; 307:382-390

Ramus SJ, Antoniou AC, et al. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 carriers. Human Mutation 2012; 33:690-702

Jakubowska A, et al. Association of PHB 1630 C>T and MTHFR  677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers – results from a multicenter study. Br J Cancer 2012; 106:2016-2024

Couch F, Gaudet MM, et al. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.Cancer Epidemiology Biomarkers Prev2012; 21:645-657

Stevens KN, Wang X, et al. Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. Breast Cancer Res Treat2012; 136:295-302

Antoniou AC, et al. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res2012 Feb 20; 14:R33, E-pub

Ding YC, Neuhausen S, et al.  A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012; 21:1362-1370